During the last session, Novavax, Inc (NASDAQ:NVAX)’s traded shares were 3.12 million, with the beta value of the company hitting 3.11. At the end of the trading day, the stock’s price was $7.87, reflecting an intraday loss of -0.25% or -$0.02. The 52-week high for the NVAX share is $23.86, that puts it down -203.18 from that peak though still a striking 51.59% gain since the share price plummeted to a 52-week low of $3.81. The company’s market capitalization is $1.27B, and the average trade volume was 4.30 million shares over the past three months.
Novavax, Inc (NVAX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.14. NVAX has a Sell rating from 0 analyst(s) out of 16 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.42.
Novavax, Inc (NASDAQ:NVAX) trade information
Novavax, Inc (NVAX) registered a -0.25% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.25% in intraday trading to $7.87, hitting a weekly high. The stock’s 5-day price performance is 11.47%, and it has moved by -6.70% in 30 days. Based on these gigs, the overall price performance for the year is 43.35%.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 64.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $25 respectively. As a result, NVAX is trading at a discount of -217.66% off the target high and -77.89% off the low.
Novavax, Inc (NVAX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -26.12% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 67.7M as predicted by 4 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 174.73M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 93.86M and 415.48M respectively. In this case, analysts expect current quarter sales to shrink by -27.87% and then drop by -57.94% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 25.88%. While earnings are projected to return 80.37% in 2025, the next five years will return 51.01% per annum.
NVAX Dividends
Novavax, Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.85 million shares, is of BLACKROCK INC.’s that is approximately 8.4669% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $149.98 million.
